Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway by Wared Nour-Eldine et al.
fphar-07-00086 April 5, 2016 Time: 11:41 # 1
ORIGINAL RESEARCH







University of Missouri, USA
Sai Wang Seto,





†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 16 December 2015
Accepted: 16 March 2016
Published: 07 April 2016
Citation:
Nour-Eldine W, Ghantous CM,
Zibara K, Dib L, Issaa H, Itani HA,
El-Zein N and Zeidan A (2016)
Adiponectin Attenuates Angiotensin
II-Induced Vascular Smooth Muscle
Cell Remodeling through Nitric Oxide




II-Induced Vascular Smooth Muscle
Cell Remodeling through Nitric Oxide
and the RhoA/ROCK Pathway
Wared Nour-Eldine1,2†, Crystal M. Ghantous1†, Kazem Zibara2, Leila Dib1,
Hawraa Issaa1,2, Hana A. Itani3, Nabil El-Zein2 and Asad Zeidan1*
1 Cardiovascular Physiology Lab, Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American
University of Beirut, Beirut, Lebanon, 2 ER045, Laboratory of Stem Cells, Department of Biology, Faculty of Sciences, The
Lebanese University, Beirut, Lebanon, 3 Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University
School of Medicine, Nashville, TN, USA
Introduction: Adiponectin (APN), an adipocytokine, exerts protective effects on cardiac
remodeling, while angiotensin II (Ang II) induces hypertension and vascular remodeling.
The potential protective role of APN on the vasculature during hypertension has not
been fully elucidated yet. Here, we evaluate the molecular mechanisms of the protective
role of APN in the physiological response of the vascular wall to Ang II.
Methods and Results: Rat aortic tissues were used to investigate the effect of APN
on Ang II-induced vascular remodeling and hypertrophy. We investigated whether nitric
oxide (NO), the RhoA/ROCK pathway, actin cytoskeleton remodeling, and reactive
oxygen species (ROS) mediate the anti-hypertrophic effect of APN. Ang II-induced
protein synthesis was attenuated by pre-treatment with APN, NO donor S-nitroso-
N-acetylpenicillamine (SNAP), or cGMP. The hypertrophic response to Ang II was
associated with a significant increase in RhoA activation and vascular force production,
which were prevented by APN and SNAP. NO was also associated with inhibition of
Ang II-induced phosphorylation of cofilin. In addition, immunohistochemistry revealed
that 24 h Ang II treatment increased the F- to G-actin ratio, an effect that was inhibited
by SNAP. Ang II-induced ROS formation and upregulation of p22phox mRNA expression
were inhibited by APN and NO. Both compounds failed to inhibit Nox1 and p47phox
expression.
Conclusion: Our results suggest that the anti-hypertrophic effects of APN are due, in
part, to NO-dependent inhibition of the RhoA/ROCK pathway and ROS formation.
Keywords: adiponectin, angiotensin II, nitric oxide, VSMC, remodeling
INTRODUCTION
Hypertension is a primary risk factor for other cardiovascular diseases, such as myocardial
infarction, cardiac hypertrophy, heart failure, atherosclerosis, and vascular hypertrophy (Zeidan
et al., 2003; Zhang et al., 2005; Pedrinelli et al., 2012). These diseases are governed by structural and
functional changes in the cardiovascular system. Angiotensin II (Ang II) is a potent vasoconstrictor
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that binds to its angiotensin receptor (AT1) in different organ
systems to increase blood pressure. In the vascular system, Ang
II binds to AT1 receptors to induce vascular smooth muscle
cell (VSMC) contraction and subsequent vasoconstriction (Bagi
et al., 2011). Moreover, Ang II promotes VSMC remodeling, cell
growth, fibrosis, collagen deposition, and contractility (Touyz,
2005; Heeneman et al., 2007).
The molecular mechanisms associated with VSMC growth
and contraction include reactive oxygen species (ROS) formation
and the activation of several signaling pathways, such as
MAPK and the RhoA/ROCK pathway (Zeidan et al., 2007).
The RhoA/ROCK pathway is activated by several hypertension-
associated factors, such as the Ang II (Carbone et al., 2015),
endothelin-1 (Et-1; Homma et al., 2007), leptin (Zeidan et al.,
2007), and mechanical stretch (Zeidan et al., 2003). Activation
of the RhoA/ROCK pathway leads to the phosphorylation and
subsequent inhibition of the actin-depolymerization enzyme
cofilin, and thus promotes formation of stress fibers, an increase
in F-actin formation, and depletion in G-actin (Zeidan et al.,
2007). Hence, the RhoA/ROCK pathway affects cell morphology,
produces modifications in actin cytoskeleton, and regulates
transcription factors leading to cellular hypertrophy (Zeidan
et al., 2006).
Nitric oxide (NO) exerts a protective role on cardiovascular
function (Jones and Bolli, 2006). Activation of endothelial nitric
oxide synthase (eNOS) produces NO, which exerts vasoprotective
effects on the vascular wall by maintaining vasodilation, anti-
coagulation, and anti-oxidation (Zhou et al., 2004). Moreover,
NO primarily mediates endothelium-dependent relaxation
through activation of soluble guanylyl cyclase, leading to an
increased production of cGMP which, in turn, activates several
phosphodiesterases and cGMP-dependent protein kinases
(Mayer et al., 1998). However, the precise mechanisms by which
NO prevents vascular pathology are not well understood.
Evidence suggests that the hypertrophic signaling pathways
triggered in response to Ang II are mediated by ROS formation
(Dai et al., 2011). The enhanced production of ROS increases
free radicles and leads to oxidative stress, which in turn induces
vascular dysfunction and remodeling (Touyz and Briones, 2011;
Montezano and Touyz, 2012). ROS is produced by a multi-
subunit complex protein called NADPH oxidase, which consists
of several membrane-bound proteins/components including
Nox1, Nox4, p22phox and cytosolic components including Rac1
and p47phox. Many studies have shown the important role of
p22phox and p47phox in Nox1 activation in VSMC (Ushio-Fukai
et al., 1996; Lavigne et al., 2001; Van Heerebeek et al., 2002).
Moreover, studies have shown the involvement of p22phox in
different agonists-induced ROS formation, including Ang II
(Ushio-Fukai et al., 1996).
Adiponectin (APN) is a circulating adipokine that plays a
protective role in the cardiovascular system (Caselli et al., 2014).
It exerts potent anti-atherosclerotic, anti-inflammatory, and anti-
diabetic effects (Shibata et al., 2005; Tajtakova et al., 2010).
Plasma APN levels negatively correlate with cardiovascular
disease, such as hypertension and metabolic disorders (Zhu et al.,
2008). Physiological concentrations of APN range between 5
and 25 µg/mL (Ouchi et al., 1999) and are significantly reduced
in hypertensive patients (Kim et al., 2013). This reduction
in adiponectin is believed to be responsible for hypertension-
associated cardiovascular diseases (Menzaghi et al., 2007; Kawai
et al., 2013). Several studies have investigated the relationship
between Ang II and adiponectin (Uchida et al., 2008; Ohashi
et al., 2011). It has been shown that adiponectin has the
ability to protect against Ang II-induced cardiac fibrosis (Fujita
et al., 2008) and prevent Ang II-induced apoptosis in human
endothelial cells (Lin et al., 2004). Furthermore, APN expression
ameliorates the development of hypertension in APN-deficient
mice and hypertensive KKAy mice (Ohashi et al., 2006). Uchida
et al. (2008) have shown that Ang II infusion decreased plasma
adiponectin levels via angiotensin receptor-1. Moreover, renin
angiotensin system inhibition was associated with increased
plasma adiponectin levels (Uchida et al., 2008).
Adiponectin is secreted predominantly by adipose tissue
(reviewed in Ghantous et al., 2015a), but several studies have
shown the ability of different tissues to produce APN (reviewed
in Ghantous et al., 2015a). Although, many investigations
have tried to uncover the molecular mechanisms responsible
for the cardioprotective effects of APN, the various signaling
mechanisms in VSMC remain unclear. In this study, we examined
whether APN exerts protective effects against Ang II-induced
vascular hypertrophy. Moreover, we investigated the possible
role of NO, ROS, RhoA/ROCK pathway, and actin cytoskeleton
dynamics.
MATERIALS AND METHODS
Rat Aorta Organ Culture
Male Sprague-Dawley rats (200–250 g) were killed by CO2, as
approved by the Animal Ethics Committee, American University
of Beirut. The thoracic aorta was isolated and stripped of the
surrounding adipose and connective tissue using N-HEPES
buffer solution (400 mmol/L NaCl, 200 mmol/L KCl, 100 mmol/L
MgCl2, 100 mmol/L HEPES, 11.5 mmol/L glucose) in 5%
penicillin-streptomycin. Aortic rings were then transferred to
DMEM/F-12 HAM culture media and incubated at 37◦C, 5%
CO2. Different inhibitors and agonists were added to the
media 1 h before adding Ang II (1 µmol/L; Sigma-Aldrich,
St. Louis, MO, USA) as follows: actin depolymerizing agent
Cytochalasin D (Cyt-D, 1 µmol/L, Sigma-Aldrich, St. Louis,
MO, USA), the NO donor S-nitroso-N-acetylpenicillamine
(SNAP, 0.1 mmol/L, Sigma-Aldrich, St. Louis, MO, USA), the
cGMP analog 8-Bromo-cGMP (cGMP, 100 µmol/L, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), the specific inhibitor of
cGMP-dependent protein kinase Rp-8-Br-PET-cGMPS (cGMPS,
50 nmol/L, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), adiponectin (5 µg/ml, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), and NG-nitro-L-arginine methyl ester (L-
NAME; 2 mmol/L, Sigma-Aldrich, St. Louis, MO, USA). The
concentrations of Ang II and all pre-treatments used in
this study were determined in preliminary studies to avoid
cytotoxicity while still maintaining effectiveness. Following
incubation, aortic rings were SNAP-frozen in liquid nitrogen and
stored.
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Measurement of Leucine Incorporation
Protein synthesis was examined by analysis of [3H]-leucine
incorporation. Endothelium-intact and denuded aortic rings
were cultured with or without inhibitors for 24 h and with
[3H]-leucine in order to measure protein synthesis as described
previously (Zeidan et al., 2003).
Vascular Function Studies
The thoracic aorta rings were placed immediately in ice-cold
HEPES-buffer solution. The composition of the HEPES-buffer
solution was in mmol/L: NaCl 135.5, KCl 5.9, CaCl2 2.5,
MgCl2 1.2, glucose 11.6, HEPES 11.6, pH = 7.4. High-K+
solution (60 mmol/L) was obtained by isomolar exchange of
NaCl for KCl. Aortic rings were cultured with/without Ang II
(1 µmol/L) for 24 h and pre-treated with/without adiponectin
(5 µg/ml), the NO donor SNAP (0.1 mmol/L), 8-Br-cGMP
(cGMP; 100 µmol/L), the specific inhibitor of cGMP-dependent
protein kinase Rp-8-Br-PET-cGMPS (cGMPS, 50 nmol/L), or
L-NAME (2 mmol/L). After that, cultured rat aortic segments
were washed and mounted in a myograph (620 M, Danish Myo
Technology, Aarhus, Denmark) and equilibrated at a resting
tension of 2 g for 45 min. The resting tension was readjusted every
15 min during equilibration time before starting the experiments.
After resting tension of each aortic ring have stabilized, maximum
isometric contraction was measured after addition of high-K+.
After that, the aortic rings were pre-contracted with 1 µmol/L
phenylephrine (PE). When the plateau was reached, a single
concentration of 1 µmol/L acetylcholine (ACh) was added to
evaluate endothelium functional integrity of the aortic rings
(Furchgott, 1983). The aortic ring was discarded if relaxation
with ACh was equal to or lower than 80% of the maximal
contraction obtained in aortic rings pre-contracted with PE.
The inability of 1 µM ACh to induce muscle relaxation in
the denuded aortic ring indicated the removal of endothelial
cells. Contractile responses to 1 µmol/L PE and subsequent
relaxing responses to 0.1 mmol/L sodium nitroprusside were
also compared in aortic ring with or without endothelium
to ensure that the VSMC was not damaged during removal
of the endothelium. Results in isometric contractions were
recorded using 620 M myograph connected to a PowerLab
4/35 data acquisition system (AD Instruments, Sydney, NSW,
Australia) and saved in a computer. Results were expressed as
mN/mm.
Protein Extraction and Western Blotting
Treated aortic rings were transferred to liquid nitrogen and
homogenized in order to extract proteins. The rings were added
to 300 µL lysis buffer (50 mmol/L Tris, pH = 8.0, 150 mmol/L
NaCl, 1% Nonidet-P40, 0.5% sodium deoxycholate) with protease
inhibitors. They were centrifuged at 9,000 rpm for 5 min at
4◦C. The supernatant protein solution was then aspirated and
quantified using Bradford assay. Equal amounts of extracted
proteins were then loaded on a 12% SDS-PAGE and transferred to
a nitrocellulose membrane. Blots were then probed with specific
antibodies, at 1:1000 dilution in 5% BSA, against RhoA, p-cofilin,
and actin (Sigma-Aldrich, St. Louis, MO, USA). Proteins were
detected using ECL immunoblotting detection system (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). The Western blot
images were acquired using a ChemiDoc MP System and Image
Lab software, followed by quantification of the blots using ImageJ
software.
RNA Isolation and Real-Time PCR
Ribonucleic acid (RNA) was isolated from control or treated
aortic rings and Real-Time PCR was done as previously
described. The primers were: Nox1 forward 5′-TTTCCTAAACT
ACCGACTC-3′ and Nox1 reverse 5′-GTGCGACAACGGA
CTATC-3′, p22phox forward 5′-TGGCCTGATCCTCATCACAG-
3′ and p22phox reverse 5′-AGGCACGGACAGCAGTAAGT-3′,
p47phox forward 5′-GCTGCCCACACCTCTTGAACTT-3′ and
p47phox reverse 5′-TCTTCAGGCAAAACCACCA-3′, and 18S
rRNA forward 5′-GTAACCCGTTGAACCCCATT-3′ and 18S
rRNA reverse 5′-CCATCCAATCGGTAGTAGCG-3′ which was
used as the housekeeping gene to normalize expression.
Analysis of RhoA Activity
To assess the effect of Ang II on RhoA activity in aortic rings,
we measured the level of RhoA–GTP using the RhoA G-LISA
Activation Assay Kit as per the manufacturer’s instructions
(Cytoskeleton, Denver, CO, USA).
Measurement of RhoA Translocation by
Western Blot
Tissue lysates obtained after homogenization were collected in
a homogenization buffer (pH = 7.5) containing 2 mmol/L
Tris, 1 mmol/L DTT, 2 mmol/L EDTA, 2 mmol/L EGTA,
50 mmol/L NaF, 0.2 mmol/L Na3VO4 and protease inhibitor
cocktail. The homogenate was then sheared using a 26G needle
and pelleted by a 10 min centrifugation at 5,000 rpm at
4◦C. The supernatant was further centrifuged at 57,000 rpm
for 60 min at 4◦C and the resulting supernatant was the
cytosolic fraction. The pellet was re-homogenized in lysis buffer
(pH = 7.5) containing 50 mmol/L Tris, 150 mmol/L NaCl,
2 mmol/L EDTA, 2 mmol/L EGTA, 50 mmol/L NaF, 0.2 mmol/L
Na3VO4, 10 mmol/L Na4PO7, 40 mmol/L ß-glycero-phosphate,
1% Triton X-100, 10% glycerol, and protease inhibitor cocktail.
The resulting homogenate was the membrane fraction. Both
fractions, cytosolic (12 µg) and membrane (25 µg) were then
blotted with anti-RhoA antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), as previously explained (Zeidan et al.,
2007).
Measurement of F/G Actin Ratio by
Western Blot
Aortic rings were homogenized and added to lysis buffer
(50 mmol/L PIPES, 50 mmol/L NaCl, 5 mmol/L MgCl2,
5 mmol/L EGTA, 5% glycerol, 0.1% Nonidet-P40, 0.1%
Triton X-100, 0.1% Tween 20, 0.1% β-mercaptoethanol,
1 mmol/L ATP, 1:100 protease inhibitor). The homogenate
was then sheared using a 26G needle and centrifuged at
2,000 rpm for 5 min at 37◦C. The resulting supernatant was
removed and then ultra-centrifuged at 100,000 g for 1 h
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at 37◦C in order to separate the F-actin from the G-actin,
present in the pellet and the supernatant respectively. The
supernatant was removed and ready to use, while the pellet
was re-suspended using Cytochalasin D (10 µmol/L) which
depolymerizes F-actin into G-actin. The solution was then
incubated on ice for 1 h and suspended up and down every
15 min. After the addition of Laemmli, resulting G- and
F-actin samples were denatured by heat then loaded on a
12% acrylamide gel and the membrane blotted with anti-




Frozen aorta tissue sections were fixed in 4% paraformaldehyde
for 15 min at room temperature, then rinsed twice with PBS,
and permeabilized with 0.2% Triton X-100 for 20 min. Blocking
was done for 1 h with a blocking solution consisting of 1% BSA
and 0.1% Triton X-100 in PBS. Sections were then incubated
overnight with anti-RhoA primary antibody at 1:100 dilution
in 1% BSA and 0.05% Tween-20, then rinsed twice with 0.1%
Tween-20. A goat anti-rabbit secondary antibody, conjugated
to Alexa Fluor (AF594 IgG, Invitrogen, USA), was then added
at 1:250 dilution in 1% BSA and 0.05% Tween-20 for 1 h in
the dark. Slides were then rinsed five times in 0.1% Tween-
20 at 10 min intervals. The nuclear stain 4′,6-diamidino-2-
phenylindole (DAPI) was used at 1:5000 dilution and sections
were incubated for 20 min in the dark. Imaging was done using a
LSM710 laser confocal microscopy (Zeiss, Germany).
Immunohistochemistry of F/G-Actin
After different treatments, blood vessels were sliced cross-
sectionally into frozen sections of 4 µm thickness and
fixed in 4% formaldehyde, 0.2% Triton X-100 in the PEM
cytoskeleton stabilizing buffer (100 mmol/L PIPES, 5 mmol/L
EGTA, 2 mmol/L MgCl2, pH = 6.9) for 20 min at room
temperature. They were then rinsed twice in PBS for a
few seconds and permeabilized with 0.2% Triton X-100
in PBS for 15 min. Thereafter, sections were blocked with
blocking solution (1% BSA and 0.1% Triton X-100 in PBS)
for 10 min and washed with PBS, followed by incubation
with 100 nmol/L red fluorescent F-actin stain (Actin-
stain 555 phalloidin, Cytoskeleton, Denver, CO, USA) and
300 nmol/L green fluorescent G-actin stain (Deoxyribonuclease
I Alexa fluor-488 conjugate, Molecular Probes, USA) in
blocking buffer for 20 min at room temperature in the
dark. Confocal images of F-actin and G-actin were captured
simultaneously with a fluorescence microscope Zeiss LSM710
(Zeiss, Germany).
Reactive Oxygen Species Analysis
Following treatment, aorta were cross-sectionally sliced (4 µm
thickness) and then stained with DHE dye conjugated to
Alexa Fluor 594 (Sigma-Aldrich, St. Louis, MO, USA) at a
concentration of 10 µmol/L in N-HEPES buffer and placed for
30 min at 37◦C, 5% CO2. Mounting dye containing DAPI was
added to the sections to stain the nuclei. Images were acquired
using LSM710 (Zeiss, Germany).
Drugs
S-nitroso-N-acetylpenicillamine was prepared as stock solution
in DMSO and diluted in the N-HEPES buffer solution.
L-NAME, Cyt-D, APN, cGMP, cGMPS were directly dissolved in
the N-HEPES buffer solution.
Control groups received same concentrations of vehicles
(diluted DMSO or N-HEPES buffer).
Statistical Analysis
Values are presented as mean ± standard error of the mean
(SEM). Data were analyzed using one-way analysis of variance
(ANOVA) or t-test. Significance was established by Tukey or
Holm-Sidak methods. p < 0.05 was considered to represent
significant differences.
RESULTS
The Effect of Adiponectin on Ang
II-Induced Protein Synthesis is Nitric
Oxide-Dependent
We investigated whether a physiological concentration of
adiponectin (5 µg/ml; Ouchi et al., 1999) had an anti-
hypertrophic effect on Ang II-induced protein synthesis in
VSMC. Endothelium-intact and denuded aortic rings were
treated with Ang II (1 µmol/L; Coles et al., 2007) for 24 h with
[3H]-leucine in order to study the effect of Ang II on protein
synthesis. In control aortic rings, which were not exposed to Ang
II, only weak protein synthesis was observed (Figure 1A). Both
endothelium-intact and denuded aortic tissue exposed to Ang II
exhibited a significant increase in protein synthesis by 190± 21%
(Figure 1A) and 180 ± 16% respectively. Pre-treatment of aortic
rings with adiponectin (5 µg/ml) for 1 h and then co-incubated
with 1 µmol/L Ang II significantly inhibited Ang II-induced
protein synthesis in endothelium-intact (127 ± 19%; Figure 1A)
and denuded aortic tissue (118± 11%).
Moreover, we determined whether inhibition of either NO
generation by L-NAME (2 mmol/L; Day et al., 1999) or
cGMP by the specific inhibitor of cGMP-dependent protein
kinase Rp-8-Br-PET-cGMPS (cGMPS, 50 nmol/L) prevented
the inhibitory effect of adiponectin on Ang II-induced protein
synthesis in endothelium-intact aortic rings. Both compounds
strongly inhibited the anti-hypertrophic action of adiponectin
(Figure 1A) to almost the control level. These data suggest
the possible role of NO synthesis and cGMP in the anti-
hypertrophic effect of adiponectin against Ang II-induced protein
synthesis.
NO/cGMP Activation Attenuates Ang
II-Induced Hypertrophy
We tested the hypothesis that the NO/cGMP pathway attenuates
Ang II-induced protein synthesis in the endothelium-intact
aortic ring. We studied the effect of the NO-donor SNAP
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FIGURE 1 | Adiponectin inhibits Ang II-induced protein synthesis and force production in rat aortic ring. Serum-starved endothelium-intact rat aortic rings
were pre-treated with adiponectin (5 µg/ml), L-NAME (2 mmol/L), cGMPS (50 nmol/L), S-nitroso-N-acetylpenicillamine (SNAP; 0.1 mmol/L), 8-Br-cGMP (cGMP;
100 µmol/L) for 1 h prior to 24 h treatment with 1 µmol/L Ang II. [3H]-leucine incorporation is shown in (A). Active stress in response to high K+ is shown in (B). Data
are shown as mean ± SEM with n = 5–6 for all groups. ∗p < 0.05 vs. without Ang II (control); #p < 0.05 vs. with Ang II.
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(0.1 mmol/L) or the cGMP analog 8-Bromo-cGMP (cGMP,
100 µmol/L; Hofbauer et al., 2002) on Ang II-induced protein
synthesis in aortic rings cultured for 24 h. Pre-treating the
endothelium-intact aortic rings with either the NO donor
SNAP (0.1 mmol/L) or 8-Br-cGMP (100 µmol/L) significantly
attenuated Ang II-induced vascular hypertrophy (Figure 1A).
The inhibition of Ang II-induced protein synthesis caused by
SNAP was reversible. Re-culturing the aortic tissue in new media
containing Ang II for 24 h made the total protein synthesis return
to control levels.
Adiponectin, NO, and cGMP Decrease
Vascular Contractility
We then examined the impact of pre-treating the aortic ring
with adiponectin (5 µg/ml), SNAP (0.1 mmol/L), or cGMP
(100 µmol/L) followed by treatment with Ang II (1 µmol/L)
for 24 h on high K+-induced vascular contractility. The force of
aortic rings was normalized to cross-sectional area in order to
have active stress. Figure 1B shows that the aortic rings cultured
for 24 h with Ang II alone had greater active stress during
high-K+ stimulation at optimal length compared to pre-treated
aortic rings with adiponectin, SNAP, or cGMP. On other hand,
pre-treating the aortic ring with L-NAME (2 mmol/L) or Rp-8-
Br-PET-cGMPS (cGMPS, 50 nmol/L) for 1 h followed by Ang II
(1 µmol/L) for 24 h significantly decreased VSMC contractility
induced by high K+ (Figure 1B).
Adiponectin Attenuates Ang II-Induced
RhoA Activation
The critical role of RhoA activation has been shown in
vascular hypertrophy and contractility induced by several factors,
including Ang II (Yamakawa et al., 2000; Molkentin and Dorn,
2001). Our aim was to study the effect of adiponectin on Ang-
II-induced RhoA activation. Figure 2A shows that exposure
of aortic rings to 1 µmol/L Ang II caused a time-dependent
increase in RhoA activation, which was evident after 5 min
FIGURE 2 | Adiponectin inhibition of Ang II-induced RhoA activation is NO-dependent. (A) Endothelium-intact rat aortic rings were treated for various times
(0, 15, 30, and 60 min) with 1 µmol/L Ang II and RhoA activation was analyzed with G-LISA kit BK121. (B) Time course of Ang II-induced RhoA translocation.
Confocal images for aortic frozen sections at different time points (0, 15, 30, 60 min) stained with DAPI (green) and anti-RhoA antibody (red). (C) Endothelium-intact
rat aortic rings were treated for 10 min with 1 µmol/L Ang II in the presence or absence of adiponectin (5 µg/ml), L-NAME (2 mmol/L), cGMPS (50 nmol/L). RhoA
activation was analyzed with G-LISA kit BK121. Data are shown as mean ± SEM and indicate fold change relative to untreated aortic ring (control). n = 6–7;
∗p < 0.05 vs. without Ang II.
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and peaked at 10 min. There appeared to be a decline in
RhoA activity with Ang II treatment for a long duration.
To determine whether Ang II-induced RhoA activation in
the aorta was associated with cytosolic RhoA translocation to
membrane, we investigated RhoA translocation in aortic rings
using immunohistochemistry. Figure 2B shows that Ang II
treatment for 30 min noticeably induced RhoA translocation
from the cytosol to the cell membrane, further indicating RhoA
activation.
We then examined whether the anti-hypertrophic effect
of adiponectin was mediated via inhibition of RhoA
activation. Endothelium-intact aortic rings were pre-treated
with adiponectin for 1 h followed by Ang II treatment for
10 min, the peak of Ang II-induced RhoA activation. Figure 2C
shows that adiponectin (5 µg/ml) significantly inhibited Ang
II-induced RhoA activation. The inhibitory effect of adiponectin
on Ang II-induced RhoA activation was attenuated by L-NAME
(2 mmol/L) and cGMPS (50 nmol/L), indicating the involvement
of NO action in the inhibitory effect of adiponectin on Ang
II-induced RhoA activation.
NO Attenuates Ang II-Induced RhoA
Activation
The ability of NO to inhibit RhoA activity has been studied
in cardiac cells (Kuwahara et al., 1999) and VSMC (Murthy
et al., 2003). In this study, we examined whether the anti-
hypertrophic effect of NO was mediated via inhibition of Ang
II-induced RhoA activation after 10 min of Ang II treatment in
endothelium-intact aortic rings. Figure 3A show that SNAP (NO
donor; 0.1 mmol/L) significantly inhibited Ang II-induced RhoA
activation (Figure 3A).
In order to examine the translocation of RhoA after
30 min of Ang II treatment, we performed a Western blot
analysis on cytosolic and membrane fractions of rat aortic
rings. In addition, we examined whether the anti-hypertrophic
FIGURE 3 | Nitric oxide (NO) inhibits Ang II-induced RhoA activation and translocation. (A) Endothelium-intact rat aortic rings were cultured for
10 min with or without 1 µmol/L Ang II pre-treated with/without SNAP and RhoA activation was analyzed with G-LISA kit BK121. (B) A representative
Western blot showing RhoA membrane fraction (RhoA m), RhoA cytosolic fraction (RhoA c) and actin (actin c) after 30 min treatment with Ang II in aortic
rings. Ang II caused a threefold increase in membrane bound RhoA whereas SNAP inhibited RhoA translocation. Each bar represents mean ± SEM value
obtained from 3 to 7 independent experiments. ∗p < 0.05 vs. without Ang II. #p < 0.05 vs. with Ang II. (C) Confocal images for aortic ring frozen sections
stained with DAPI (green) and anti-RhoA antibody (red) treated with Ang II for 30 min with or without SNAP. Control (left panel), Ang II (middle panel), Ang II
+ SNAP (right panel).
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effect of NO was mediated via inhibition of Ang II-induced
RhoA translocation, using SNAP. Treatment with Ang II
significantly increased RhoA translocation from the cytosol
to the cell membrane by almost threefold as compared to
controls (Figures 3B,C). This was assessed as the ratio of total
RhoA in the membrane to that in the cytosol. As expected,
SNAP significantly inhibited Ang II-induced RhoA translocation
(Figures 3B,C).
NO Attenuates Ang II-Induced Cofilin-2
Phosphorylation
To further confirm RhoA translocation and activation as
a potential mediator of Ang II-induced hypertrophy in
endothelium-intact aortic rings, we assessed the phosphorylation
of cofilin-2, an actin depolymerizing protein and a downstream
effector of RhoA/ROCK activation. Ang II (1 µmol/L)
significantly increased cofilin-2 phosphorylation, as compared
to control, in a time-dependent manner, with a peak at
15 min (∗p < 0.05, Figure 4A). This indicates that cofilin-
2 is phosphorylated and thus inhibited by Ang II-induced
RhoA translocation, an indicator of RhoA/ROCK pathway
activation. In order to investigate whether NO modulates Ang
II-induced cofilin-2 phosphorylation, SNAP (0.1 mmol/L)
was used as source of NO. Figure 4B shows that Ang
II-induced cofilin-2 phosphorylation was significantly
inhibited by NO in comparison to Ang II alone after 15 min
(∗p< 0.05).
FIGURE 4 | Nitric oxide attenuates Ang II-induced RhoA/ROCK pathway activation and actin cytoskeleton remodeling. (A) Endothelium-intact rat aortic
rings were treated for various times (0, 15, 30, and 60 min) with 1 µmol/L Ang II and cofilin-2 phosphorylation was analyzed by Western Blotting. n = 5; ∗p < 0.05.
(B) SNAP significantly inhibited Ang II-induced cofilin-2 phosphorylation after 15 min. Endothelium-intact rat aortic rings were treated with Ang II for 24 h with or
without SNAP followed by quantification of F/G-actin ratio (C). Confocal images of aortic ring sections stained with DAPI (blue, nucleus), Deoxyribonuclease-I Alexa
Fluor 488 (green, G-actin) and F-Phalloidin-555 actin stain (red, F-actin). Rat aortas were treated for 24 h with 1 µmol/L Ang II in the presence or absence of SNAP
(0.1 mmol/L) or Cyt-D (1 µmol/L) and relative amounts of F- and G-actin were assessed (D). n = 5–7; ∗p < 0.05 vs. without Ang II; #p < 0.05 vs. with Ang II.
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NO Modulates Ang II-Induced Actin
Cytoskeleton Remodeling
Previous studies demonstrated that actin cytoskeleton dynamics
are the major target of phosphorylated cofilin-2 in the
RhoA/ROCK pathway (Zeidan et al., 2006). In this study we
investigated the effect of Ang II treatment for 24 h on variations
of F- to G-actin ratio in endothelium-intact aortic rings. Ang II
(1 µmol/L) significantly increased F/G-actin ratio by fourfold,
indicating a large pool of filamentous F-actin in comparison
to G-actin (∗p < 0.05, Figure 4C). However, this effect was
completely inhibited by SNAP treatment (Figure 4C). Thus,
Ang II-activation of RhoA indeed induces changes in actin
cytoskeleton dynamics, which is inhibited by NO.
To further confirm our findings, confocal microscopy was
performed (Figure 4D) using Phalloidin and Deoxyribonuclease
I to stain F-actin (red) and G-actin (green), respectively. The
nuclei of VSMC were stained with DAPI for DNA (blue). Control
aortic ring sections showed more G-actin compared to F-actin
(Figure 4D). On the other hand, Ang II-treated aortic rings for
24 h showed a significant increase in F-actin compared to G-actin
(Figure 4D). However, F-actin was markedly decreased following
SNAP (0.1 mmol/L) or Cyt-D (1 µmol/L; Ghantous et al., 2015b)
treatment (Figure 4D). These results suggest that the protective
effect of NO is mediated by actin cytoskeleton dynamics through
increasing F/G-actin ratio.
Adiponectin and NO Inhibit Ang
II-Induced ROS Production
Reactive oxygen species has been shown to be implicated in the
development of vascular hypertrophy (Ghantous et al., 2015b).
In order to determine whether Ang II-induced hypertrophy
is associated with ROS production, endothelium-intact aortic
rings were stained with DHE and viewed using a laser confocal
microscope. Untreated aortic section barely generated ROS
(Figure 5A). Ang II treatment for 1 h noticeably upregulated ROS
formation in comparison to control aortas (Figure 5A). However,
adiponectin and SNAP completely inhibited Ang II-induced ROS
production (Figure 5A), as compared to Ang II-treated aortas.
FIGURE 5 | Nitric oxide mediates the inhibitory effect of adiponectin on Ang II-induced ROS formation and p22phox mRNA overexpression.
(A) Representative confocal microscopic images of aortic wall treated with Ang II for 1 h, with or without inhibitors and agonists, followed by staining with DHE (red).
DAPI stained the nuclei blue. Fold change of Nox1 (B), p22phox (C), and p47phox (D) mRNA expression levels in the aortic rings after 0, 1, 3, 6, 18, 24 h of Ang II
(1 µmol/L) treatment. n = 8–10 in each group; ∗p < 0.05 vs. control, #p < 0.05 vs. with Ang II.
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The inhibitory effect of adiponectin on Ang II-induced ROS
formation (for 1 h) was abolished by L-NAME, indicating the
involvement of NO action in the inhibitory effect of adiponectin
on Ang II-induced ROS formation.
Ang II-Induced p22phox mRNA
Expression is Inhibited by NO and cGMP
NADPH oxidase (Nox) expression and activity are critical factors
for ROS formation in various cells types, including VSMC.
To examine whether Ang II enhanced the expression of Nox1
mRNA, endothelium-intact aortic rings were stimulated with
Ang II (1 µmol/L) for 1, 3, 6, 18, or 24 h and the mRNA
expressions of Nox1 was analyzed using qPCR. Figure 5B
shows that Ang II significantly enhanced Nox1 expression after
1 h and was further enhanced up to 24 h. We also assessed
whether adiponectin (5 µg/ml) could prevent the Ang II-induced
upregulation of Nox1 mRNA expression using qPCR analysis.
Figure 5B shows that adiponectin and adiponectin + L-NAME
had no effect on Ang II-induced Nox1 overexpression.
To explore further the involvement p47phox and p22phox
on Ang II-induced ROS formation in VSMC, we investigated
whether the expression of p47phox and p22phox mRNA in
endothelium-intact aortic rings could be modified by Ang
II treatment. Ang II significantly increased both p47phox
and p22phox mRNA expression in a time-dependent manner
(Figures 5C,D). Upregulation of p47phox mRNA expression
induced by Ang II was not affected when aortic rings were
pre-treated with adiponectin compared with the controls
(Figure 5D). On the other hand, adiponectin significantly
decreased p22phox mRNA expression compared with the Ang
II-treated group (Figure 5C). Collectively, these data indicate
the inhibitory effect of adiponectin on Ang II-induced p22phox
overexpression but not on Ang II-induced Nox1 or p47phox
overexpression.
To determine whether adiponectin inhibits Ang II-induced
p22phox overexpression through NO synthesis, L-NAME was
used. Figure 5C shows L-NAME significantly attenuates the
inhibitory effect of adiponectin on Ang II-induced p22phox
overexpression in endothelium-intact aortic rings. Next, we
determined whether increased Nox1, p47phox, or p22phox mRNA
expression by Ang II was inhibited by SNAP or cGMP. Neither
NO or cGMP had any effect on Ang II-induced Nox1 or
p47phox expression (Figures 6A,C). Similar to adiponectin effect,
NO and cGMP significantly inhibited Ang II-induced p22phox
overexpression (Figure 6B).
FIGURE 6 | S-nitroso-N-acetylpenicillamine and cGMP attenuate Ang II-induced p22phox mRNA expression. Fold change of Nox1 (A), p22phox (B), and
p47phox (C) mRNA expression levels in the endothelium-intact rat aortic rings after 0, 1, 3, 6, 18, 24 h of Ang II (1 µmol/L) treatment. n = 8–10 in each group;
∗p < 0.05 vs. control; #p < 0.05 vs. with Ang II.
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FIGURE 7 | Proposed model of adiponectin-mediated inhibition of Ang
II-induced VSMC remodeling. Treatment with Ang II induces hypertrophy in
VSMC. Adiponectin suppresses AngII-induced VSMC hypertrophy through
signaling pathways that activates NO synthesis in endothelial cells (ECs). The
inhibitory effect of adiponectin on Ang II-induced VSMC hypertrophy is
mediated through modulating the RhoA/ROCK signaling pathway, F-actin to
G-actin ratio, and ROS formation.
DISCUSSION
Hypertension is a key risk factor for cardiovascular disease.
Abnormal vascular structure and function, such as hypertrophy,
increased constrictor, or decreased dilatory responses, are major
aspects underlying vascular pathology in hypertension (Touyz,
2003). Ang II, an endogenous vasoconstrictor, contributes to
these aspects mainly by inducing vascular hypertrophy (Zhang
et al., 2005; Li et al., 2011). The ability of Ang II to activate both
ROS production and RhoA/ROCK pathway has been previously
investigated, suggesting the emergence of these pathways as
critical components of the hypertrophy program (Zeidan et al.,
2005; Jin et al., 2006) and as such represent possible targets
for therapeutic intervention. The purpose of our study was to
investigate whether the anti-hypertrophic effect of adiponectin
on Ang II-induced hypertrophy is mediated by NO synthesis and
due to inhibition of RhoA activation and ROS formation.
To our knowledge, the major novel findings in our study are
(1) adiponectin attenuates Ang II-induced VSMC hypertrophy,
(2) adiponectin displays anti-oxidant effects and suppresses the
expression of p22phox mRNA expression, but not Nox1 and
p47phox mRNA expression in Ang II-stimulated aortic rings, and
(3) the anti-hypertrophic and anti-oxidant effects of adiponectin
are mediated by NO synthesis and action (Figure 7).
Recent studies portrayed adiponectin as a cardioprotective
hormone in obesity-related diseases, such as hypertrophic
cardiomyopathy, and its ability to maintain the cardiovascular
function (Ouchi et al., 2006; Kitaoka et al., 2010). Indeed,
in contrast to other adipokines, circulating APN levels are
reduced in cardiovascular diseases (Shetty et al., 2009). The
effects of APN occur through interaction with specific APN
receptors, AdipoR1 and AdipoR2. These receptors are expressed
in several cells including VSMC (reviewed by Ghantous et al.,
2015a). Upon binding to its receptors, adiponectin activates
several signal transduction pathways mediated by AMPK and
PPARα (Yamauchi and Kadowaki, 2013). Through activation
of AMP-activated protein kinase signaling, adiponectin has
been demonstrated to inhibit the hypertrophic effect of Ang
II on cardiac tissue (Wang et al., 2010). Adiponectin-deficient
mice exposed to pressure overload showed increased cardiac
hypertrophy, while supplementation of adiponectin protected
against the development of cardiac hypertrophy in response to
angiotensin II (Shibata et al., 2004). To our knowledge, there
aren’t studies done on angiotensin II-infusion in adiponectin
receptor-deficient mice. However, angiotensin II-infusion done
on normal rats induced cardiac hypertrophy and reduced
the expression of AdipoR1 but not AdipoR2 (Li et al.,
2013). Angiotensin II-infusion also reduced circulating levels of
adiponectin (Li et al., 2013).
To date and to our knowledge, there are no studies that have
examined the anti-hypertrophic effect of adiponectin in Ang
II-induced vascular hypertrophy. In this study, we approached
this question and we showed the anti-hypertrophic effect of
adiponectin on Ang II-induced vascular hypertrophy. The next
step was to understand the molecular mechanism of the anti-
hypertrophic effect of adiponectin. Increasing attention has
recently been focused on the role of ROS in adiponectin
signal transduction (Fujimoto et al., 2010; Yuan et al., 2012).
Accumulating evidence suggests that ROS is involved in the
hypertrophic responses to Ang II (Schiffrin and Touyz, 2003;
Dai et al., 2011). ROS mediates VSMC hypertrophy through
activation of different signaling pathways such as ERK1/2,
different transcription factors, and ion channels. NADPH
oxidase (Nox) generates superoxides that affect different cellular
functions (Hingtgen et al., 2006). Nox1, an isoform of Nox family,
exists in VSMC and participates in many vascular functions, such
as muscle contraction (Matsuno et al., 2005). Nox1 is composed
of several subunits including p22phox and p47phox. Both p22phox
and p47phox are necessary for Nox1 function and stability
(Lambeth, 2004), which leads to ROS formation. Additionally,
several studies have shown that Ang II induces ROS formation
through upregulation of different NADPH oxidase subunits,
including Nox1, p47phox, and p22phox in cardiac and vascular cells
(Touyz et al., 2005; Thomas et al., 2006). Our results in this study
show, in the first place, that adiponectin has the ability to inhibit
Ang II-induced ROS formation and p22phox mRNA expression.
Interestingly, treatment with adiponectin failed to inhibit the
expression of both Nox1 and p47phox. As far as we know, this is
the first report of the protective effect of adiponectin on ROS and
downregulation of p22phox mRNA expression.
To evaluate the molecular mechanisms underlying the
inhibitory effect of adiponectin on ROS formation and p22phox
mRNA expression in Ang II-stimulated aortic rings, we
investigated the influence of the NO synthesis inhibitor L-
NAME on adiponectin’s anti-oxidant effect. NO has many
cardioprotective actions on the cardiovascular system during
hypertension (Tanaka and Node, 2015). The major functions of
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NO on the cardiovascular system include anti-inflammatory,
anti-proliferative, anti-thrombotic, and anti-hypertrophic
activity (Tziros and Freedman, 2006; Garcia and Incerpi, 2008;
Momi et al., 2012). However, the exact molecular mechanisms
of the anti-hypertrophic effect of NO on Ang II-induced
VSMC hypertrophy remain unclear. VSMC contractility is
associated with hypertrophy when exposed to high stress such as
hypertension. We and others have shown that Ang II significantly
increased the VSMC force-generating ability in response to high-
K+ depolarization (Garcha et al., 2001). Different studies have
shown the involvement of the RhoA/ROCK pathway, which is
activated by Ang II (Yamakawa et al., 2000), in VSMC contraction
(Sakamoto et al., 2003; Zeidan et al., 2003). The observed increase
in force generation was associated with increased fiber stress
formation (increased F-actin to G-actin ratio). Indeed, actin
cytoskeleton remodeling and stress formation are a well-
described consequence of RhoA/ROCK pathway activation
(Zeidan et al., 2007). It is reasonable to speculate that actin
cytoskeleton modulation would increase the contractile potential
of VSMC. Another potential factor that leads to increased
force production is myosin light chain phosphatase (MLCP).
Inhibition of MLCP by RhoA/ROCK pathway has been shown
to increase calcium sensitivity, leading to an increase in muscle
contraction (Mizuno et al., 2008).
In this study we have investigated the role of Rho A activation
and translocation in Ang II -induced VSMC remodeling. To
activate the RhoA/ROCK pathway, RhoA must first be activated
by binding to GTP [by guanine nucleotide exchange factors
(GEFs)], then translocated to the cell membrane, followed
by subsequent activation of ROCK and the pathway (Zeidan
et al., 2007). We have shown that Ang II treatment caused
a significant activation in RhoA after 5 min, which peaked
after 10 min (Figure 2A). We then examined whether RhoA
activation was followed by its translocation to the membrane.
Ang II treatment for 15 min showed some RhoA translocation
to the membrane, while 30 min of Ang II treatment induced
a marked increase in RhoA translocation (Figure 2B). Hence,
RhoA activation after 10 min of Ang II treatment was indeed
followed by its translocation to the membrane, which began
after 15 min and peaked after 30 min of Ang II treatment.
Since changes in F-actin and G-actin cytoskeleton dynamics are
the downstream targets of RhoA/ROCK pathway, their levels
were examined. Indeed, time-course experiments for F- and
G-actin cytoskeleton dynamics (unpublished data) showed that
the changes are most prominent after 24 h, in both VSMC and
cardiomyocytes (Zeidan et al., 2006, 2007, 2008; Ghantous et al.,
2015b).
Nitric oxide is a gaseous molecule that acts as a vasodilating
factor in VSMC while it’s an anti-hypertrophic factor in
both VSMC and cardiomyocytes (Hunter et al., 2009; Van
Hove et al., 2009). It diffuses easily to VSMC, across the
plasma membrane, and causes their relaxation by reducing
intracellular calcium levels (Van Hove et al., 2009). NO attenuates
VSMC contraction and hypertrophy by inhibiting ROCK in
the RhoA/ROCK pathway (Maruhashi et al., 2014). The anti-
hypertrophic effect of NO is associated with vasodilatory actions
though cGMP formation and phosphorylation of PKG (Kapakos
et al., 2010). Our data show that culturing endothelium-intact
aortic rings either with NO or adiponectin in presence of Ang
II for 24 h significantly decreased force production of aorta
in response to high-K+ depolarization compared to tissues
cultured with Ang II alone. Inhibition of NO synthesis by
L-NAME or cGMP-dependent protein kinase by Rp-8-r-PET-
cGMPS (cGMPS) ameliorated adiponectin’s effect on Ang II-
induced force production and ROS formation, indicating the
necessity of NO/cGMP pathway for the inhibitory effect of
adiponectin against Ang II-induced increased in muscle force
production, and ROS formation. This data provide insight
into how this circulating adipokine might attenuate Ang II-
induced vasoconstriction and ROS formation through NO
production.
To further explore another possible mechanism of the anti-
hypertrophic effect of adiponectin, we attempted to investigate
the involvement of the RhoA/ROCK pathway. Indeed, numerous
studies have implicated the potential involvement of RhoA
activation and increased stress fiber formation with the
hypertrophic effect of Ang II (Yamakawa et al., 2000; Jin et al.,
2006). Upon stimulation, RhoA activates a signaling cascade
involving ROCK, LIMK, and cofilin-2, an actin depolymerizing
enzyme that binds to actin and prevents stress fiber formation
(Zeidan et al., 2007). As such, when cofilin-2 is phosphorylated
(inactivated) by LIMK, the F/G-actin equilibrium is shifted
toward enhanced stress fiber formation or more F-actin
formation (Zeidan et al., 2008). Consistent with the previously
reported findings (Hunter et al., 2009; Zeidan et al., 2014), our
results also demonstrate that Ang II-induced RhoA activation
and translocation are associated with cofilin-2 phosphorylation
and enhanced stress fiber formation, which were abolished
by treatment with NO synthesis. The effect of Ang II on
cofilin-2 phosphorylation and actin cytoskeleton remodeling was
abolished in aortic tissue treated with NO donor, indicating
that the anti-hypertrophic effect of NO may be mediated via
inhibition of RhoA activation and its downstream signaling. In
addition, we showed that the ability of adiponectin to modulate
the effect of Ang II on RhoA activation and actin cytoskeleton
dynamics was mediated through NO synthesis.
Overall, our study provides insight into the signal transduction
pathway mediating the anti-hypertrophic properties of
adiponectin during hypertension. The proposed mechanism
underlying the anti-hypertrophic effect of adiponectin on
Ang II-induced hypertrophy is shown in Figure 7. Our study
highlights the effects of adiponectin on cellular NO synthesis,
ROS generation, RhoA/ROCK pathway, and actin cytoskeleton
dynamics. Our findings could be useful in the development of
novel adiponectin-targeted therapeutic interventions for the
treatment of vascular hypertrophy during hypertension.
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